文献速递类风湿关节炎

两剂新冠疫苗接种与类风湿关节炎患者可能的关节炎发作

Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong.
PubMed 文献 · Ann Rheum Dis · 2021-10-22

基于香港人群电子病历的倾向加权队列研究纳入5493例类风湿关节炎患者,比较BNT162b2、CoronaVac与未接种组。结果显示全程接种与可能的关节炎发作无显著关联,BNT162b2调整发病率比0.86(95%CI 0.73–1.01),CoronaVac为0.87(0.74–1.02); weekly抗风湿药物处方分布三组无显著差异。

要点

  • 全程接种mRNA或灭活新冠疫苗与RA可能的关节炎发作无显著关联。
  • BNT162b2调整发病率比0.86(95%CI 0.73–1.01),CoronaVac为0.87(0.74–1.02)。
  • 接种计划启动后每周抗风湿药物处方三组分布无显著差异(Kruskal-Wallis检验所有p值>0.1)。

核心结论

  • 当前证据不支持mRNA或灭活病毒新冠疫苗全程接种与可能的关节炎发作相关。

研究设计与样本

  • 基于人群电子病历与疫苗接种链接识别类风湿关节炎患者,采用倾向加权队列设计比较接种与未接种组。
  • 共纳入5493例RA患者,其中BNT162b2组653例、CoronaVac组671例、未接种组4169例。

主要发现

  • 倾向评分加权Poisson回归显示关节炎发作与新冠疫苗接种无显著关联,BNT162b2调整发病率比0.86(95%CI 0.73–1.01),CoronaVac为0.87(0.74–1.02)。
  • 自大规模接种计划启动以来,三组每周抗风湿药物处方分布无显著差异(Kruskal-Wallis检验所有p值>0.1)。

关键数值与推荐

  • 可能的关节炎发作定义为基于发作期间诊断记录的与RA或反应性关节炎相关的住院和门诊就诊。

临床怎么用

  • 临床可依据此证据向RA患者说明全程接种BNT162b2或CoronaVac未显示增加可能的关节炎发作风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the relationship between COVID-19 full vaccination (two completed doses) and possible arthritis flare. METHODS: Patients with rheumatoid arthritis (RA) were identified from population-based electronic medical records with vaccination linkage and categorised into BNT162b2 (mRNA vaccine), CoronaVac (inactive virus vaccine) and non-vaccinated groups. The risk of possible arthritis flare after vaccination was compared using a propensity-weighted cohort study design. We defined possible arthritis flare as hospitalisation and outpatient consultation related to RA or reactive arthritis, based on diagnosis records during the episode. Weekly prescriptions of rheumatic drugs since the launch of COVID-19 vaccination programme were compared to complement the findings from a diagnosis-based analysis. RESULTS: Among 5493 patients with RA (BNT162b2: 653; CoronaVac: 671; non-vaccinated: 4169), propensity-scored weighted Poisson regression showed no significant association between arthritis flare and COVID-19 vaccination ((BNT162b2: adjusted incidence rate ratio 0.86, 95% Confidence Interval 0.73 to 1.01); CoronaVac: 0.87 (0.74 to 1.02)). The distribution of weekly rheumatic drug prescriptions showed no significant differences among the three groups since the launch of the mass vaccination programme (all p values >0.1 from Kruskal-Wallis test). CONCLUSIONS: Current evidence does not support that full vaccination of mRNA or inactivated virus COVID-19 vaccines is associated with possible arthritis flare.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Li X, Tong X, Yeung WWY, et al. Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis. 2021. PMID: 34686479. doi:10.1136/annrheumdis-2021-221571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。